107 related articles for article (PubMed ID: 7554288)
1. Erythropoietin secretion in liver disease.
Siciliano M; Tomasello D; Milani A; Ricerca BM; Storti S; Rossi L
Clin Chim Acta; 1995 May; 236(2):217-8. PubMed ID: 7554288
[No Abstract] [Full Text] [Related]
2. Erythropoietin alterations in human liver disease.
Mirand EA; Murphy GP
N Y State J Med; 1971 Apr; 71(8):860-4. PubMed ID: 5279354
[No Abstract] [Full Text] [Related]
3. [Secretion of mesobilifuscine in diseases of the liver].
Netousek M; Moravec M
Acta Hepatosplenol; 1965; 12(5):279-84. PubMed ID: 5866829
[No Abstract] [Full Text] [Related]
4. Porphyrin metabolism in normal and some hepatic affections in Egyptian children.
Abdel Kader MM; Shukry AS; Abdel Salam E; Maraghi S; Emara SH
Gaz Egypt Paediatr Assoc; 1973 Oct; 21(4):63-8. PubMed ID: 4804966
[No Abstract] [Full Text] [Related]
5. Erythropoietin response to post-liver transplantation anemia.
Vasilopoulos S; Hally R; Caro J; Martin P; Westerberg S; Moritz M; Jarrell B; Muñoz S
Liver Transpl; 2000 May; 6(3):349-55. PubMed ID: 10827238
[TBL] [Abstract][Full Text] [Related]
6. [A clinical study of serum erythropoietin concentrations in patients with liver cirrhosis and hepatocellular carcinomas].
Takezaki E; Murakami S; Kagawa K; Omori H; Nishibayashi H
Gan No Rinsho; 1990 Jan; 36(1):19-22. PubMed ID: 2153846
[TBL] [Abstract][Full Text] [Related]
7. [The enzymogram in chronic hepatitis and hepatic cirrhosis].
BRAUNER R; SORU E; IULIAN M; NEGOESCU V; HOANCA O
Rev Int Hepatol; 1961; 11():509-28. PubMed ID: 13872624
[No Abstract] [Full Text] [Related]
8. [On the histopathology of liver injury, especially of cirrhosis in connection with the liver content of copper and iron. Differentiation by histochemical and quantitative chemical assay].
NISHIMURA H
Acta Pathol Jpn; 1962 Jan; 12():59-89. PubMed ID: 14479972
[No Abstract] [Full Text] [Related]
9. Evidence for an erythropoietin-stimulating factor in patients with renal and hepatic disease.
Naughton BA; Liu P; Naughton GK; Gordon AS
Acta Haematol; 1983; 69(3):171-9. PubMed ID: 6404100
[TBL] [Abstract][Full Text] [Related]
10. [Effect of chronic liver diseases on the endocrine system].
Rühle H
Z Arztl Fortbild (Jena); 1983; 77(10):415-8. PubMed ID: 6880261
[No Abstract] [Full Text] [Related]
11. [Activity of granulocytic alkaline phosphatase in parenchymal liver diseases of varied etiology].
Wichrzycka E; Pawelski S
Pol Tyg Lek; 1966 Jan; 21(3):86-8. PubMed ID: 5907711
[No Abstract] [Full Text] [Related]
12. Renal retention of sodium in cirrhosis and fulminant hepatic failure.
Wilkinson SP; Moodie H; Alam A; Williams R
Postgrad Med J; 1975 Aug; 51(598):527-31. PubMed ID: 1234336
[TBL] [Abstract][Full Text] [Related]
13. Verapamil bioavailability and dosage in liver disease.
Woodcock BG; Rietbrock N
Br J Clin Pharmacol; 1982 Feb; 13(2):240-1. PubMed ID: 7059425
[No Abstract] [Full Text] [Related]
14. [Carbohydrate metabolism in liver diseases].
Mosin VI
Klin Med (Mosk); 1974 Feb; 52(2):. PubMed ID: 4619410
[No Abstract] [Full Text] [Related]
15. [Angiotensin-converting enzyme inhibitors in liver function disorders?].
Bönner G
Dtsch Med Wochenschr; 1996 Feb; 121(8):254. PubMed ID: 8815027
[No Abstract] [Full Text] [Related]
16. Ammonium and glucose metabolism in liver failure.
Brown H; Brown ME; Covelli VH; McDermott WV
JAMA; 1967 Sep; 201(11):873-4. PubMed ID: 6071907
[No Abstract] [Full Text] [Related]
17. [Malabsorption in liver disease (author's transl)].
Teichmann W
Przegl Lek; 1975; 32(10):774-7. PubMed ID: 1197811
[No Abstract] [Full Text] [Related]
18. [Distribution of biliary lipids in healthy subjects, in liver cirrhosis, fatty liver and in cholecystitis].
Erb W; Kautzsch S
Z Gastroenterol; 1971; 9(6):447-60. PubMed ID: 5164737
[No Abstract] [Full Text] [Related]
19. Liver disease of the alcoholic: pathogenesis and metabolic complications.
Lieber CS
Ala J Med Sci; 1975 Oct; 12(4):355-60. PubMed ID: 1200320
[No Abstract] [Full Text] [Related]
20. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic oxidation capacity.
O'Keefe SJ; Abraham R; El-Zayadi A; Marshall W; Davis M; Williams R
Gastroenterology; 1981 Dec; 81(6):1017-24. PubMed ID: 7286580
[No Abstract] [Full Text] [Related]
[Next] [New Search]
